WO2005059118A2 - Stem cell targeting using magnetic particles - Google Patents
Stem cell targeting using magnetic particles Download PDFInfo
- Publication number
- WO2005059118A2 WO2005059118A2 PCT/GB2004/005156 GB2004005156W WO2005059118A2 WO 2005059118 A2 WO2005059118 A2 WO 2005059118A2 GB 2004005156 W GB2004005156 W GB 2004005156W WO 2005059118 A2 WO2005059118 A2 WO 2005059118A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- use according
- cell
- particle
- cells
- magnetisable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
Definitions
- This invention relates to a novel method of magnetically manipulating stem cells ex vivo or in vivo and to methods of treatment related thereto.
- stem cells in the form of a cell-based therapies is currently one of the most exciting and promising areas for disease treatment and reparative medicine.
- basic research into the ways by which proliferation and differentiation of e.g. embryonic and adult stem cells can be controlled is vitally important.
- US Patent No. 6,548,264 describes silica coated nanoparticles which comprise a magnetic metal core.
- the magnetic core present in the particles enables the particles to be responsive to a magnetic field and therefore, the particles are suitable for use in diagnostic, imaging and recording systems.
- the nanoparticles of the prior art may suffer from the disadvantage that they do not define the method of activation at a cellular level.
- Magnetic bead twisting cytometry has been used to define the mechanical properties of single cells and to demonstrate that external mechanical forces can be transmitted across the cell surface and through the cytoskeleton via transmembrane cell adhesion molecules such as integrins, see, for example, Wang, N and Ingberger, DE (1995) Probing transmembrane mechanical coupling and cytomechanics using magnetic twisting cytometry. Biochem. Cell Biol. 73: 327-335.
- Bone marrow contains multipotential stromal stem cells or mesenchymal stem cells which can differentiate into, ter alia, fibroblastic, osteogenic, adipogenic and reticular cells.
- mesenchymal stem cells such as human bone marrow stromal fibroblasts can be isolated from volunteer donors and may retain their multilineage (adipocytic, chondrogenic, osteoblastic) potential.
- One advantage in the use and manipulation of the aforementioned cells lies in their lack of immunogenicity which provides the potential for use of these cells in, inter alia, cartilage and bone repair.
- Figure 2 shows the results of experiments using bone marrow stromal cells with internal calcium levels up- regulated as a result of the application of magnetic fields to magnetic nanoparticles attached to a His-tagged TREK channel.
- stem cells tagged with magnetic nanoparticles can be delivered to or held at, a particular repair site by external magnetic manipulation.
- these concepts further to include remote activation of specific cellular membrane receptors, which in essence, involves localising cells e.g. stem cells. More simply this involves deposition of stem cells at a site e.g. a repair site, retaining the cells at the site and remotely activating the cells in situ vvithin the patient.
- the present invention addresses issues of targeting specific receptors on cells for remote activation of transmembrane ion channels in stem cells.
- magnetic nanoparticle-based technologies are increasingly used clinically, in many facets of healthcare e.g. contrast enhancement for MRI.
- the achieved differentiation acts as a model for binding strategies which allows both remote targeting within the body and/or activation at specific sites when localised.
- the present invention enables the targeting of a variety of stem cell receptor types, such as mechano-activated ion channels e.g. K+ channels (TREK), calcium channels, integrins and surface membrane binding sites such as RGD, present in human bone marrow stem cells.
- stem cell receptor types such as mechano-activated ion channels e.g. K+ channels (TREK), calcium channels, integrins and surface membrane binding sites such as RGD, present in human bone marrow stem cells.
- TREK mechano-activated ion channels
- calcium channels e.g. K+ channels (TREK)
- integrins e.g., calcium channels
- RGD surface membrane binding sites
- the targeting of other known receptors such as external growth factors (e.g. TGFB and BMP2) which have been shown to activate downstream transcription factors such as Runx2 and Osterix, critical for stem cell differentiation can also be achieved.
- TGFB and BMP2 external growth factors
- the present invention provides the opportunity for true engraftment of, inter alia, human mesenchymal stem cells, long-term biological effects on the stem cells at the site of injury or repair. Furthermore, the ability to select, expand and differentiate these cells and target the cells using magnetic nanoparticles is especially advantageous. Furthermore, utilisation of the present invention provides therapeutic implications in, inter alia, gene therapy and tissue engineering.
- Biocompatible magnetic nanoparticles primarily composed of a magnetite (Fe 3 O ) and/or maghemite (Fe O 3 ) core with either a silica, dextran, or PNA coating may be utilised in the present invention.
- Such particles may be synthesized following methods known in the art. However, it will be understood that other magnetic nanoparticles may be utilised. Particle sizes can range from -lOnm up to a few microns e.g. 1 to lO ⁇ m. Commercially available magnetic micro- and nanoparticles with varying surface chemistry may also be used.
- the coatings may be functionalized and crosslinked to membrane attachment motifs such as those described above.
- the magnetic nanoparticles may be modified so as to customise, inter alia, particle internalization frequency and binding efficiency and stability will be examined as will the effects of binding on cell viability and function. Modification may also include customisation of internal binding sites as well as sites on the outer membrane.
- a variety of coatings may be used in magnetic nanoparticle binding and loading in human osteoblasts 14 ' 15 and these techniques may be further optimized for stem cell binding, delivery and activation e.g. using adult primary marrow human stem cells and/or human embryonic stem cells.
- high gradient magnets e.g. external rare earth (primarily NdFeB), high-gradient magnets
- NdFeB external rare earth
- high-gradient magnets may be used to target the stem cells to specific sites within an in vitro test system and/or in vivo.
- Such magnets produce high field/gradient products which exert a translational force on the magnetic particles loaded onto the cells, holding them at the target site according to the equation:
- Remote mechanical activation may be achieved using e.g. a magnetic conditioning bioreactor.
- bioreactors which are known per se, enable forces to be applied to magnetic particles attached to cells cultured in vitro within a multi-well 2D system or in vivo a 3D scaffold-based system.
- Stem cells e.g. Mesenchymal stem cells and populations generated therefrom, such as osteogenic, chondrogenic and adipogenic populations may be isolated using, for example, magnetic activated cell sorting (MACS) with a monoclonal antibody e.g. STRO-1 using standard protocols 'known per se x ⁇
- MCS magnetic activated cell sorting
- STRO-1 monoclonal antibody
- Such protocols include those known for BMSc culture in monolayer .and using 3D scaffolds composed of biodegradable polymers such as poly lactic acid 91
- PLLA collagen gels
- a remote manner it is intended to mean, e.g. a non-contacting manner and in the case of in vivo activating/targeting specifically from outside the body.
- a method of magnetically manipulating a stem cell in vivo or in vitro which comprises the association of a magnetisable particle with a stem cell.
- the method may comprise ex vivo manipulation of an in vivo process.
- a reference to a cell shall be construed to include a plurality of cells.
- the invention provides a method as hereinbefore described which comprises the activation and/or targeting of a magnetisable particle with a stem cell as hereinbefore described.
- a method of magnetically manipulating a stem cell which comprises the association of a magnetisable particle with a cell characterised in that the method comprises agonising or antagonising ion channels within a cell by the association of a magnetisable particle with a cell.
- the magnetisable particle may be associated directly with the cell.
- the method may comprise associating the magnetisable particle with an antibody, enzyme, etc., which is subsequently associated with the cell.
- the association of a magnetisable particle with a cell may comprise the introduction of such a particle into a cell, the attachment of such a particle to a cell, e.g. externally or internally to a cell, or any combination thereof.
- the magnetisable particles may be associated intracellularly or extracellularly or a combination of intracellularly and extracellularly.
- the particles are associated intracellularly.
- this will comprise association with an internal binding site.
- the particle(s) may be associated with the N-te ⁇ riinus region of the ion channel.
- the particle(s) may be associated with the COOH terminus region of the ion channel.
- ion channels and binding sites may be utilised in the method of the invention.
- internal binding sites which correspond to the N-terminus region of the ion channel, as seen in TREK- lor which corresponds to the COOH terminus region ofthe ion channel, as seen in TREK-1 may be utilised as well as other binding sites known per se.
- the method of the invention may comprise the manipulation of mammalian cells or other cell types, such as bacterial cells, plant cells, etc. However, it will be understood by the skilled man that the method of the present invention may be used to manipulate other cell types not mentioned herein. Furthermore, the method may be an in vitro method or an in vivo method, although an in vivo method is preferred.
- the method of the invention may comprise the up-regulation or down-regulation of gene expression in stem cells in response to mechanical manipulation of the stem cells as described herein.
- the stem cells may be induced to follow particular differentiation pathways such as described herein.
- the method of the invention comprises the remote manipulation of cells and/or of agonising or autagonising ion channels, e.g. manipulation from outside the body., i.e. remote mechanical activation.
- the method ofthe invention may be utilised in relation to a variety of cells which are known per se. However, preferentially, the method is suitable for use with mammalian stem cells.
- the method of the invention may be utilised in connection with any conventionally known ion channels within the cell which are hereinbefore described.
- the method is especially suited for use in mechanosensitive ion channels.
- mechanosensitive ion channels have been identified in many cell types and have been predominantly described as calcium or potassium ion channels, although it should be understood that the method of the invention is not limited to use in relation to calcium or potassium ion channels.
- one such channel which has been well characterised at the molecular level and at the functional level in neuronal cells is the chromosomal gene TREK-1, which is part of the 2P K+ channel family.
- TREK-1 channels have been identified in bone cells, and are known to respond to shear stress, cell swelling and membrane stretch as well as other external agents such as fatty acids and general anaesthetics.
- a particular aspect of the present invention is to provide a method of manipulating mechanosensitive ion channels.
- these channels are instrumental in normal cellular function and play a particularly important role in, for example, the production of bone and connective tissue or activation ofthe peripheral nervous system, the ability to manipulate them remotely, e.g. from outside the body, is especially advantageous an provides applications in, ter alia, pain relief, e.g. anaesthetics, therapeutics, tissue engineering and repair and cancer therapy.
- the method may also be suitable for use with conventionally non mechanosensitive cells and/or ion channels by the transfection of channels into cells which may otherwise be otherwise non-responsive.
- Noltage-gated and ligand-gated ion channels are also "mechanoresponsive" in that they respond to mechanical stresses on the ion channel generated by coulomb forces (in the case of voltage-gated channels) and binding forces (in the case of ligand-gated channels). As such, all ion channels can be activated by the method described herein provided that the magnetisable particle is coupled, either directly or indirectly, to the mechanoresponsive region ofthe channel protein.
- the ion channel is a voltage-gated ion channel, alternatively, the ion channel is a ligand-gated ion channel.
- the magnetisable particle used in the method ofthe invention may be inherently magnetic or, alternatively, may be one which reacts in a magnetic field.
- any magnetic material may be used, however, by the term magnetic we mean, for example, a material which is paramagnetic superparamagnetic, ferromagnetic and/or antiferromagnetic, examples of which include elemental iron (Fe), or an compound, e.g. an iron salt, such as, magnetite (Fe 3 O 4 ), maghemite ( ⁇ Fe 2 O 3 ), and greigite (Fe 3 S 4 ), or a chromium compound, e.g.
- the magnetic material comprises particles, e.g. nanoparticles, which comprises a magnetic core with a biocompatible coating.
- particles e.g. nanoparticles, which comprises a magnetic core with a biocompatible coating.
- such preferred particles are nanoparticles and especially nanoparticles having a core and, e.g. a silica shell enveloping the core.
- porous particles with multiple magnetic centres within the pores are those nanoparticles described in US Patent No. 6,548,264 which is incorporated herein by reference.
- the prior art nanoparticles may have a mean size of less than 1 micron, each of said nanoparticles comprising (a) a core comprising a magnetisable particle and (b) a silica shell enveloping the core, wherein the magnetisable particle is a magnetic material as hereinbefore described.
- the micro- and nano- particles (intended to be attached to the cells) will generally be substantially spherical or elliptical.
- the size of the particles may vary according, inter alia, to the nature of the magnetisable material, the application, etc.
- an example of particles may be nanoparticles can having a mean size, e.g. diameter, of 5000 nm or less, e.g. from 1 nm to 5000 nm, preferably from 1 nm to 1000 nm, more preferably from 1 nm to 300 nm, or from 2 nm to 10 nm).
- the particles for attachment to the cells may be coated or uncoated and single or multi-domain.
- suitable particles include, but are not limited to:
- the ion channels may be activated by attaching the magnetisable particles as hereinbefore described to specific regions of the cellular membrane and/or to specific "receptors" on the ion channels themselves.
- the mechanical forces required to activate the channels can then be applied remotely by a magnetic field acting on these magnetic particles.
- the method of the invention comprises modifying a magnetisable particle as hereinbefore described by tagging the particle with one or more specific antibodies or protein binding motifs which recognise key cellular elements within a cell.
- transmembrane adhesion molecules such as integrins, cadherins, selectins, and immunoglobulins or dispersed membrane adhesion proteins such as RGD (argiiiine-glycine-aspartate), see, for example, . J. Chen, B. Fabry, E. L. Schiffrin, and N. Wang (2001) Twisting integrin receptors increases endothelin-1 gene expression in endothelial cells Am JPhysiol Cell Physiol. 280: 1475-84 ; A. R. Bausch, U. Hellerer, M. Essler, M. Aepfelbacher, and E.
- the method ofthe invention is especially advantageous because it provides a method of treatment of a variety of disorders. Indeed the invention provides a method of treatment which is applicable to any disorder in which one or more ion channels play a role. In addition, the invention provides a method for potential control of ion channel activation including pain relief, e.g. an anaesthetic role.
- the method of treatment as hereinbefore described should not be considered to be limited, but it is especially advantageous in tissue and/or bone repair.
- the method of treatment can be to facilitate further treatment by providing a method of pain relief, e.g. for localised anaesthesia, to targeted regions ofthe body.
- the nature of such cells may vary depending upon the nature ofthe tissue of interest.
- the cells may be ligamentum cells for growing new ligaments, tenocytes for growing new tendon.
- the cells may be chondrocytes and/or other stromal cells, such as chondrocyte progenitor cells.
- the method of the invention may include the regeneration of tissue or the generation of artificial tissue, such as skin, cartilage, ligament, tendon, muscle or bone.
- the method may comprise wound healing and/or tissue adhesion.
- the method may comprise bone repair and/or bone growth.
- the method of the invention may include, for example, dental applications and/or veterinary applications.
- the method also may be used as a mechanism for selectively killing cells (such as tumour cells) in vivo.
- magnetisable particles are attached to the target cell membrane or ion channel protein and a magnetic field is applied to the in vivo target region.
- the rapid, cyclic opening and closing (via the application of a time varying magnetic field), and/or the holding open (via the application of a static magnetic field) of ion channels in the cell membrane allows ions (such as Ca " " " ) to flood the cell, inducing osmotic shock and, consequently, cell death.
- a method of destroying cells or inhibiting cell growth which comprises agonising or antagonising ion channels within a cell which by the association of a magnetisable particle with a cell.
- the method may comprise a method of inducing osmotic shock to a cell, e.g. by agonising or antagonising ion channels within a cell by the association of a magnetisable particle with a cell.
- the method is especially useful in the treatment or alleviation of a tumour cell, e.g. a cancer cell.
- the method may comprise the killing of cells by holding ion channels open with a targeted static magnetic field.
- the method may comprise the killing of cells via cyclically opening and closing ion channels with a targeted, time- varying magnetic field.
- the magnetic field may be varied depending upon, inter alia, the nature of the disorder to be treated, but may be, for example, at a frequency of from 0.1 to 10 Hz. But, frequencies outside this range can also be used.
- the magnetic field will typically have a flux density in the order of (but not limited to) 10 mT to 1400 mT.
- the magnetic field may be generated outside the body for the case of in vivo applications, and may be provided by a permanent magnet or an electromagnet.
- the magnetic field may be a constant or a variable field, e.g. a permanent magnet may be moved relative to the cells.
- a magnetic field may be generated by provision of appropriate electric current levels to the electromagnetic, optionally, in combination with alternating current.
- a method of inducing a therapeutic effect in a cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell and magnetically manipulating the magnetisable particle.
- a method of treatment which comprises the administration of a therapeutically active agent which may be administered simultaneously, separately or sequentially with a magnetisable particle whilst agonising or antagonising ion channels vvithin the cell.
- the use may comprise ex vivo manipulation of an in vivo process. More particularly, the invention provides the use of a magnetisable particle in the manufacture of a system for magnetically manipulating a cell which system comprises the association of a magnetisable particle with a cell and agonising or antagonising ion channels witliin the cell.
- the magnetisable particle may be associated directly with the cell.
- the use may comprise associating the magnetisable particle with an antibody, enzyme, etc., which is subsequently associated with the cell.
- the particle(s) may be associated with the N-terminus region of the ion channel.
- the particle(s) may be associated with the COOH terminus region ofthe ion channel.
- the use ofthe invention may comprise the manipulation of mammalian cells or other cell types, such as bacterial cells, plant cells, etc.
- the use may be an in vitro use or an in vivo use, although an in vivo use is preferred.
- the use of the invention comprises the remote manipulation of cells and/or of agonising or autagonising ion channels, e.g. manipulation from outside the body, i.e. remote mechanical activation.
- the use of the invention may be utilised in relation to a variety of cells, which are known per se.
- the use is suitable for use with mammalian somatic cells, for example, bone, cartilage, muscle (skeletal and cardiac) lymphatic cells, endocrine cells, urinary system cells, cells relating to the reproduction system, neuronal cells and tumour cells.
- the use of the invention may be utilised in connection with any conventionally known ion channels within the cell, which is hereinbefore described.
- the use is especially suited for use in mechanosensitive ion channels hereinbefore described.
- a particular aspect of the present invention is to provide the use in the manufacture of a system for manipulating mechanosensitive ion channels.
- the use may also be suitable for use with conventionally non mechanosensitive cells and/or ion channels by the transfection of channels into cells which may otherwise be otherwise non-responsive.
- the ion channel is a voltage-gated ion channel, alternatively, the ion channel is a ligand-gated ion channel.
- any magnetisable material may be used, examples of which include elemental iron (Fe), or an iron compound, e.g. an iron salt, such as, magnetite (Fe 3 O 4 ), maghemite ( ⁇ Fe 2 O 3 ), and greigite (Fe 3 S 4 ), or a chromium compound, e.g. a chromium salt, such as, chromium oxide (CrO 2 ), or any combination thereof.
- the magnetic material comprises particles which comprises a magnetic core with a biocompatible coating.
- such preferred particles are nanoparticles and especially nanoparticles having a core and, e.g. a silica shell enveloping the core.
- porous particles with multiple magnetic centres within the pores are those nanoparticles described in US Patent No. 6,548,264 which is incorporated herein by reference.
- the use of the invention comprises modifying a magnetisable particle as hereinbefore described by tagging the particle with one or more specific antibodies or protein binding motifs which recognise key cellular elements within a cell.
- These include transmembrane adhesion molecules, such as integrins, cadherins, selectins, and immunoglobulins or dispersed membrane adhesion proteins such as RGD (arginine-glycine-aspartate) .
- the use of the invention is especially advantageous because it provides a system suitable for use in the treatment of a variety of disorders.
- the invention provides the use in the manufacture of a medicament suitable for a treatment, which is applicable to any disorder in which one or more ion channels play a role.
- the invention provides the use for potential control of ion channel activation including pain relief, e.g. an anaesthetic role.
- a magnetisable particle in the manufacture of a medicament suitable for the treatment of a patient suffering from a disorder in which an ion channel plays a role which comprises the administration to such a patient of magnetisable particles as hereinbefore described and manipulating those particles using a magnetic field.
- the use as hereinbefore described should not be considered to be limited, but it is especially advantageous in tissue and/or bone repair.
- the use can be to facilitate further treatment by providing a method of pain relief, e.g. for localised anaesthesia, to targeted regions ofthe body.
- the nature of such cells may vary depending upon the nature ofthe tissue of interest.
- the cells may be ligamentum cells for growing new ligaments, tenocytes for growing new tendon.
- the cells may be chondrocytes and/or other stromal cells, such as chondrocyte progenitor cells.
- the use may include the regeneration of tissue or the generation of artificial tissue, such as skin, cartilage, ligament, tendon, muscle or bone.
- the use may comprise wound healing and/or tissue adhesion.
- the use may comprise bone repair and/or bone growth.
- the use ofthe invention may include, for example, dental applications and/or veterinary applications.
- the use also may be used as a mechanism for selectively killing cells (such as tumour cells) in vivo as hereinbefore described.
- a magnetisable particle in the manufacture of a system for destroying cells or inhibiting cell growth which comprises agonising or antagonising ion channels within a cell which by the association of a magnetisable particle with a cell.
- the use may comprise use in a method of inducing osmotic shock to a cell, e.g. by agonising or antagonising ion channels within a cell by the association of a magnetisable particle with a cell.
- the use in this aspect of the invention is especially useful in the treatment or alleviation of a tumour cell, e.g. a cancer cell.
- the use may comprise the killing of cells by holding ion channels open with a targeted static magnetic field.
- the use may comprise the killing of cells via cyclically opening and closing ion channels with a targeted, time- varying magnetic field.
- a magnetisable particle in the manufacture of a system for inducing a therapeutic effect in a cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell and magnetically manipulating the magnetisable particle.
- a magnetisable particle in the manufacture of a system comprising a therapeutically active agent which may be administered simultaneously, separately or sequentially with the magnetisable particle whilst agonising or antagonising ion channels within the cell.
- a magnetisable particle in the manufacture of a system for targeting a therapeutically active agent to a cell which comprises agonising or antagonising ion channels within the cell by the association of a magnetisable particle with the cell, magnetically manipulating the magnetisable particle and simultaneously, separately or sequentially administering the therapeutically active agent.
- kits comprising a therapeutically active agent and means for associating a magnetisable particle with a cell.
- the kit may comprise a vessel containing a therapeutically active agent, a source of magnetisable particles and instructions for the simultaneous, sequential or separate a ⁇ 'ministration thereof.
- the kit of the invention may also include other agents known er se.
- the invention may also include the use of a kit as hereinbefore described in the manufacture of a medicament.
- Figure lb illustrates primary human astrocytes with membrane bound RGD coated carboxyl ferromagnetic particles (4 ⁇ m) (magnification x 1000);
- Figure 2 is a schematic of the TREK ion channel showing structure and location of the His. tags present in the protein. Red circles indicate the sites ofthe His tags at the three sites, the primary loop, the COOH terminus and the NH terminus;
- Figure 3 is a representation of the magnetic activation of Trek-1 monitored via downstream changes in intracellular calcium
- Figure 4 is a representation of the magnetic activation of TREK-1 induces transient rise in intracellular calcium in HEK293 T cells co-transfected with and Flashpericam.
- the model system consists of a peristaltic pump connected to tubing which feeds into channels witnin agar gel blocks.
- the magnets can be placed at various positions in relation to the channels and the magnetic field and gradient at the target site is measured using an axial Hall probe interfaced to a gaussmeter.
- the magnetic fields generated by the rare earth magnets will be characterised using a Redcliffe Diagnostics MagScan field mapping system requested for this project.
- the gel channel will be excised and assayed for cell capture using staining techniques. Magnetic particle capture will be quantified by performing Superconducting Quantum Interference Device (SQUID) magnetometry measurements on the freeze dried gel blocks.
- Models may be used to optimize the delivery and targeting parameters, such as magnetic field strength and geometry, magnetic particle characteristics, number of particles per cell, etc.
- scaffolds are seeded with 10 6 -10 9 BMSc dependant on scaffold size and cultured for 24 hours prior to placing within the bioreactor. Constructs are then subjected to varying magnetic loading regimes, e.g. 1 hour at 1 Hz frequency with forces ranging from 1-lOOpN per particle. These parameters are controllable and will allow optimisation of the system for varying cell types and scaffold materials. Following treatment, cells may be removed and subjected to RNA and protein analysis at varying points after activation.
- osteoblastic transcription factors such as runx 2 and osterix
- matrix proteins such as osteopontin, collagen type 1, alkaline phosphatase and osteocalcin.
- Animal trials of this technology support the ability to remotely activate stem cells to promote bone call differentiation and new bone formation by cells held in vivo within subcutaneous diffusion chambers using a mouse SCID model. In this way, comparisons can be made with in vitro experiments. Targeting of cells to specific tissues in vivo may also be advised.
- Human-derived osteoprogenitors from mesenchymal stem cells may be used.
- In vivo bone formation may be assessed using the subcutaneous implant model in severely compromised immunodeficient (SCID) mice and the diffusion chamber model.
- SCID immunodeficient
- This provides a rapid and robust model to validate, in vivo, the efficacy for targeting of magnetic micro- and nanoparticles and provides a clear demonstration of bone formation.
- the diffusion chamber assay provides unequivocal demonstration of bone formation by implanted cells as opposed to host cells.
- the subcutaneous implant model remains the industry standard for the assessment of skeletal tissue formation and one of us (RO) has published on the use of both the sc and DC models under a project license to RO (30/1759) for assessment of skeletal tissue engineering 22 .
- selected human osteoprogenitor cells will be implanted subcutaneously in SCID mice for four weeks while for diffusion chamber studies, cells and magnetic particle composites will be placed into each diffusion chamber and the chambers implanted intraperitoneally into athymic nude mice (MFI-nu-nu; 4-6 weeks old; Harlan UK Ltd) for 10 weeks. Thereafter, diffusion chambers will be removed, fixed overnight (95% ethanol, 4°C) and embedded undecalcified in poly(hydroxymethylmethacrylate) resin at 4°C. New bone formation will be assessed by histological techniques including frozen, paraffin and methylmethacrylate plastic sections.
- Magnetic microparticles (d-4 ⁇ m) were coated with a biotinylated ⁇ 2 / ⁇ -l subunit of a voltage gated calcium ion channel receptor antibody. After 4 days, particles were attached to the stem cells for 40 minutes via the calcium channel receptor. After 40 minutes, the cells were exposed to a 1Hz magnetic field which applied a force of approximately 30 picoNewtons per particle ( ⁇ 2 particles/cell). After 2 hours 40 minutes, the particles were detached from the cells and removed by aspiration. The original culture media was returned to the samples which were then further cultured for another 24 hour period. RNA from the control and stimulated groups was collected at day five. Gene microarray analysis was performed on each of the samples. 8000 genes/sample were analysed using HG-Focus human genome chips (Affymetrix UK Ltd) in response to magnetic activation (upregulation and downregulation taken as two fold increase/decrease).
- Microarray data from these experiments showed that the mechanical stimulation resulted in the downregulation of certain genes such as nerve growth factor and fibroblast growth factor (Table 1). This is an indication that the application of mechanical force using magnetic particles is guiding the stem cell differentiation away from the neuronal and fibroblast pathways.
- the upregulation of genes such as tetranectin in response to the mechanical force application indicates a differentiation of the cells towards an osteogenic pathway. Upregulation of genes involved in cytoskeletal reorganisation and cell adhesion proteins correlate with expected cell processes after force application.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004299704A AU2004299704A1 (en) | 2003-12-18 | 2004-12-08 | Method |
US10/596,594 US8469034B2 (en) | 2003-12-18 | 2004-12-08 | Stem cell targeting and activation using magnetic particles |
CA002550084A CA2550084A1 (en) | 2003-12-18 | 2004-12-08 | Stem cell targeting using magnetic particles |
EP04805976A EP1699917A2 (en) | 2003-12-18 | 2004-12-08 | Stem cell targeting using magnetic particles |
JP2006544539A JP2007518710A (en) | 2003-12-18 | 2004-12-08 | Method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0329310.7A GB0329310D0 (en) | 2003-12-18 | 2003-12-18 | Method |
GB0329310.7 | 2003-12-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005059118A2 true WO2005059118A2 (en) | 2005-06-30 |
WO2005059118A3 WO2005059118A3 (en) | 2006-05-26 |
Family
ID=30471287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/005156 WO2005059118A2 (en) | 2003-12-18 | 2004-12-08 | Stem cell targeting using magnetic particles |
Country Status (9)
Country | Link |
---|---|
US (1) | US8469034B2 (en) |
EP (1) | EP1699917A2 (en) |
JP (1) | JP2007518710A (en) |
KR (1) | KR20060124654A (en) |
CN (1) | CN1898378A (en) |
AU (1) | AU2004299704A1 (en) |
CA (1) | CA2550084A1 (en) |
GB (1) | GB0329310D0 (en) |
WO (1) | WO2005059118A2 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005123907A2 (en) * | 2004-06-15 | 2005-12-29 | Baxter International Inc. | Ex-vivo application of solid microparticulate therapeutic agents |
WO2007113572A1 (en) * | 2006-04-03 | 2007-10-11 | Keele University | Targeted therapy |
JP2007269770A (en) * | 2006-03-09 | 2007-10-18 | Mitsubishi Chemicals Corp | Functional magnetic super-nanoparticle and use thereof |
KR100792185B1 (en) | 2006-06-30 | 2008-01-07 | 재단법인서울대학교산학협력재단 | Method for Fixing or Mobilizing Cells Using Magnetic Nanoparticle |
JP2008541734A (en) * | 2005-05-30 | 2008-11-27 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | Production and use of basement membrane particles |
US7553662B2 (en) | 2000-12-22 | 2009-06-30 | Keele University | Culturing tissue using magnetically generated mechanical stresses |
WO2010077168A1 (en) * | 2008-12-30 | 2010-07-08 | Bryukhovetskiy Andrey Stepanovich | Drug made from stem cells with reprogrammed cell signaling, method for producing said preparation and the use thereof |
EP2249800A2 (en) * | 2008-02-04 | 2010-11-17 | University Of Miami | Magnetic cells for localizing delivery and tissue repair |
WO2011047277A3 (en) * | 2009-10-15 | 2011-08-18 | The Brigham And Women's Hospital, Inc. | Release of agents from cells |
CN102895652A (en) * | 2011-07-27 | 2013-01-30 | 东北师范大学 | Method for promoting osteoblast differentiation by using Runx2 and Osterix and application thereof |
WO2013049598A1 (en) * | 2011-09-28 | 2013-04-04 | Board Of Regents Of The University Of Texas System | Alternating electric current directs, enhances, and accelerates mesenchymal stem cell differentiation into osteoblasts and chondrocytes but not adipocytes |
US8447379B2 (en) | 2006-11-16 | 2013-05-21 | Senior Scientific, LLC | Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof |
US8469034B2 (en) | 2003-12-18 | 2013-06-25 | Mica Biosystems Limited | Stem cell targeting and activation using magnetic particles |
US8662085B2 (en) | 2010-03-02 | 2014-03-04 | Siemens Aktiengesellschaft | Magnetic nanoparticle and group of nanoparticles |
US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
US8999650B2 (en) | 2004-03-01 | 2015-04-07 | Senior Scientific Llc | Magnetic needle biopsy |
US9044381B2 (en) | 2003-06-24 | 2015-06-02 | Baxter International Inc. | Method for delivering drugs to the brain |
US9095270B2 (en) | 2009-11-06 | 2015-08-04 | Senior Scientific Llc | Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof |
US9364443B2 (en) | 2008-03-05 | 2016-06-14 | Baxter International, Inc. | Compositions and methods for drug delivery |
US9964469B2 (en) | 2005-02-28 | 2018-05-08 | Imagion Biosystems, Inc. | Magnetic needle separation and optical monitoring |
US10194825B2 (en) | 2009-11-06 | 2019-02-05 | Imagion Biosystems Inc. | Methods and apparatuses for the localization and treatment of disease such as cancer |
US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (en) | 2003-07-31 | 2005-02-01 | Univ Roma | PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA. |
GB0405552D0 (en) * | 2004-03-12 | 2004-04-21 | Magnet Attraction Ltd | Methods for the targetted delivery of biological molecules |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
WO2008156904A2 (en) * | 2007-04-09 | 2008-12-24 | Children's Medical Center Corporation | Systems and methods for nanomagnetic actuation of molecular cell signaling |
FR2950362B1 (en) * | 2009-09-21 | 2011-10-21 | Univ Clermont Auvergne | USE OF K2P POTASSIUM CHANNEL ACTIVATORS AS ANALGIC. |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US9669200B2 (en) * | 2010-08-06 | 2017-06-06 | Boston Scientific Scimed, Inc. | Systems and methods for the treatment of pelvic disorders including magnetic particulates |
US9180172B2 (en) | 2010-12-15 | 2015-11-10 | Ams Research Corporation | Treatment of Peyronies disease |
US8979797B2 (en) | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
WO2013029025A1 (en) | 2011-08-24 | 2013-02-28 | The Rockefeller University | Compositions and methods to modulate cell activity |
WO2013059528A2 (en) * | 2011-10-18 | 2013-04-25 | City Of Hope | Encapsulated diagnostics and therapeutics in nanoparticles-conjugated to tropic cells and methods for their use |
US9023612B2 (en) | 2012-01-13 | 2015-05-05 | Bell Biosystems, Inc. | Eukaryotic cells with artificial endosymbionts for multimodal detection |
US8956873B2 (en) | 2012-01-13 | 2015-02-17 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
US8828681B2 (en) | 2012-01-13 | 2014-09-09 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
US10076579B2 (en) | 2012-01-13 | 2018-09-18 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
CA2881394A1 (en) | 2012-08-13 | 2014-02-20 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
WO2014145785A1 (en) | 2013-03-15 | 2014-09-18 | Bell Biosystems, Llc | Host cells with artificial endosymbionts |
CN103289965A (en) * | 2013-07-01 | 2013-09-11 | 浙江大学 | Virus AAVMTF for expressing iron nano-particles and temperature sensitive channels and use thereof |
CN103333919A (en) * | 2013-07-01 | 2013-10-02 | 浙江大学 | Viruses AAVSTF for expressing iron nano particles and temperature-sensitive channel and application thereof |
US10557120B2 (en) * | 2013-07-26 | 2020-02-11 | Kyoto Prefectural Public University Corporation | Osteoblast and method for preparing same |
AU2014315321A1 (en) | 2013-09-03 | 2016-03-03 | Bell Biosystems, Inc. | Host cell modification with artificial endosymbionts |
KR101743539B1 (en) * | 2014-04-02 | 2017-06-08 | 동국대학교 산학협력단 | Method For Differentiation Of Adult Stem Cells Into Nerve Cells Using High Intensity Of Electromagnetic Field |
US10696728B2 (en) | 2014-07-03 | 2020-06-30 | Chunlei Liu | Polypeptides, related nucleic acids, and their uses for cell modulation and treatments |
CA2962052A1 (en) | 2014-09-22 | 2016-03-31 | Rensselaer Polytechnic Institute | Compositions and methods to modulate cell activity |
CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
ES2574655B1 (en) * | 2014-11-21 | 2017-04-20 | Universidad De Granada | Elaboration of artificial tissues comprising magnetic particles |
CN107847429B (en) * | 2015-06-19 | 2021-01-22 | 梁平 | Method for targeting or stimulating cells or organisms using nanoparticles and external field |
CN106691542A (en) * | 2015-07-17 | 2017-05-24 | 成昱 | Stem cell mediated magnetic knife and preparation method and application of same |
US11253551B2 (en) | 2016-01-11 | 2022-02-22 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
US11518971B2 (en) | 2018-11-27 | 2022-12-06 | Research Triangle Institute | Method and apparatus for spatial control of cellular growth |
CN110680831A (en) * | 2019-10-30 | 2020-01-14 | 扬州大学 | New application of ferroferric oxide nanoenzyme |
CN114432497B (en) * | 2020-10-30 | 2023-11-24 | 江千里 | Micro-magnet net film and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032397A2 (en) * | 2000-10-18 | 2002-04-25 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessing in drug delivery and cell encapsulation |
WO2002051985A2 (en) * | 2000-12-22 | 2002-07-04 | Keele University | Culturing tissue using magnetically generated mechanical stresses |
WO2004000369A2 (en) * | 2002-06-19 | 2003-12-31 | Keele University | Method of magnetically manipulating a cell with magnetisable particles |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105017A (en) * | 1976-11-17 | 1978-08-08 | Electro-Biology, Inc. | Modification of the growth repair and maintenance behavior of living tissue and cells by a specific and selective change in electrical environment |
US5183336A (en) * | 1992-01-21 | 1993-02-02 | Kontes Glass Company | Stirring assembly |
US5486457A (en) | 1993-08-25 | 1996-01-23 | Children's Medical Center Corporation | Method and system for measurement of mechanical properties of molecules and cells |
US5842477A (en) * | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
US6197586B1 (en) * | 1997-12-12 | 2001-03-06 | The Regents Of The University Of California | Chondrocyte-like cells useful for tissue engineering and methods |
US6649408B2 (en) * | 2000-03-24 | 2003-11-18 | George Mason University | Microdroplet cell culture technique |
US6548264B1 (en) | 2000-05-17 | 2003-04-15 | University Of Florida | Coated nanoparticles |
US7553662B2 (en) * | 2000-12-22 | 2009-06-30 | Keele University | Culturing tissue using magnetically generated mechanical stresses |
GB0329310D0 (en) | 2003-12-18 | 2004-01-21 | Univ Keele | Method |
-
2003
- 2003-12-18 GB GBGB0329310.7A patent/GB0329310D0/en not_active Ceased
-
2004
- 2004-12-08 CN CNA2004800380433A patent/CN1898378A/en active Pending
- 2004-12-08 CA CA002550084A patent/CA2550084A1/en not_active Abandoned
- 2004-12-08 JP JP2006544539A patent/JP2007518710A/en active Pending
- 2004-12-08 WO PCT/GB2004/005156 patent/WO2005059118A2/en active Application Filing
- 2004-12-08 US US10/596,594 patent/US8469034B2/en active Active
- 2004-12-08 EP EP04805976A patent/EP1699917A2/en not_active Ceased
- 2004-12-08 KR KR1020067012067A patent/KR20060124654A/en not_active Application Discontinuation
- 2004-12-08 AU AU2004299704A patent/AU2004299704A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032397A2 (en) * | 2000-10-18 | 2002-04-25 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessing in drug delivery and cell encapsulation |
WO2002051985A2 (en) * | 2000-12-22 | 2002-07-04 | Keele University | Culturing tissue using magnetically generated mechanical stresses |
WO2004000369A2 (en) * | 2002-06-19 | 2003-12-31 | Keele University | Method of magnetically manipulating a cell with magnetisable particles |
Non-Patent Citations (4)
Title |
---|
CARTMELL S H ET AL: "Development of magnetic particle techniques for long-term culture of bone cells with intermittent mechanical activation" IEEE TRANSACTIONS ON NANOBIOSCIENCE IEEE USA, vol. 1, no. 2, June 2002 (2002-06), pages 92-97, XP011077118 ISSN: 1536-1241 * |
CARTMELL S H ET AL: "Development of magnetic particle techniques for long-term culture of bone cells with intermittent mechanical activation" IEEE TRANSACTIONS ON NANOBIOSCIENCE, IEEE SERVICE CENTER, PISCATAWAY, NY, US, vol. 1, no. 2, June 2002 (2002-06), pages 92-97, XP001152893 ISSN: 1536-1241 * |
FROHLICH M W ET AL: "Ex Vivo Activation and Expansion of T Cells from the Peripheral Blood of Multiple Myeloma Patients Using the XcellerateTM Process" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 100, no. 11, 16 November 2002 (2002-11-16), XP002296916 ISSN: 0006-4971 * |
LEWIN M ET AL: "Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 18, April 2000 (2000-04), pages 410-414, XP002958421 ISSN: 1087-0156 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7553662B2 (en) | 2000-12-22 | 2009-06-30 | Keele University | Culturing tissue using magnetically generated mechanical stresses |
US9044381B2 (en) | 2003-06-24 | 2015-06-02 | Baxter International Inc. | Method for delivering drugs to the brain |
US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
US8469034B2 (en) | 2003-12-18 | 2013-06-25 | Mica Biosystems Limited | Stem cell targeting and activation using magnetic particles |
US8999650B2 (en) | 2004-03-01 | 2015-04-07 | Senior Scientific Llc | Magnetic needle biopsy |
WO2005123907A3 (en) * | 2004-06-15 | 2007-08-23 | Baxter Int | Ex-vivo application of solid microparticulate therapeutic agents |
WO2005123907A2 (en) * | 2004-06-15 | 2005-12-29 | Baxter International Inc. | Ex-vivo application of solid microparticulate therapeutic agents |
US8333959B2 (en) | 2004-06-15 | 2012-12-18 | Baxter International Inc. | Ex-vivo application of solid microparticulate therapeutic agents |
US10900872B2 (en) | 2005-02-28 | 2021-01-26 | Imagion Biosystems Inc. | Magnetic needle separation and optical monitoring |
US9964469B2 (en) | 2005-02-28 | 2018-05-08 | Imagion Biosystems, Inc. | Magnetic needle separation and optical monitoring |
JP2008541734A (en) * | 2005-05-30 | 2008-11-27 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | Production and use of basement membrane particles |
JP2007269770A (en) * | 2006-03-09 | 2007-10-18 | Mitsubishi Chemicals Corp | Functional magnetic super-nanoparticle and use thereof |
WO2007113572A1 (en) * | 2006-04-03 | 2007-10-11 | Keele University | Targeted therapy |
KR100792185B1 (en) | 2006-06-30 | 2008-01-07 | 재단법인서울대학교산학협력재단 | Method for Fixing or Mobilizing Cells Using Magnetic Nanoparticle |
US8447379B2 (en) | 2006-11-16 | 2013-05-21 | Senior Scientific, LLC | Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof |
EP2249800A2 (en) * | 2008-02-04 | 2010-11-17 | University Of Miami | Magnetic cells for localizing delivery and tissue repair |
US9078932B2 (en) | 2008-02-04 | 2015-07-14 | Emmetrope, Inc. | Magnetic cells for localizing delivery and tissue repair |
EP2249800A4 (en) * | 2008-02-04 | 2014-09-24 | Jeffrey L Goldberg | Magnetic cells for localizing delivery and tissue repair |
US9364443B2 (en) | 2008-03-05 | 2016-06-14 | Baxter International, Inc. | Compositions and methods for drug delivery |
US20110268774A1 (en) * | 2008-12-30 | 2011-11-03 | Andrey Stepanovich Bryukhovetskiy | preparation of stem cells with reprogrammed cell signalling, a method of producing the preparation and a method of use thereof |
WO2010077168A1 (en) * | 2008-12-30 | 2010-07-08 | Bryukhovetskiy Andrey Stepanovich | Drug made from stem cells with reprogrammed cell signaling, method for producing said preparation and the use thereof |
US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
US8956863B2 (en) | 2009-10-15 | 2015-02-17 | The Brigham And Women's Hospital, Inc. | Agents from cells |
WO2011047277A3 (en) * | 2009-10-15 | 2011-08-18 | The Brigham And Women's Hospital, Inc. | Release of agents from cells |
US9884129B2 (en) | 2009-10-15 | 2018-02-06 | The Brigham And Women's Hospital, Inc. | Release of agents from cells |
US9095270B2 (en) | 2009-11-06 | 2015-08-04 | Senior Scientific Llc | Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof |
US10194825B2 (en) | 2009-11-06 | 2019-02-05 | Imagion Biosystems Inc. | Methods and apparatuses for the localization and treatment of disease such as cancer |
US8662085B2 (en) | 2010-03-02 | 2014-03-04 | Siemens Aktiengesellschaft | Magnetic nanoparticle and group of nanoparticles |
CN102895652A (en) * | 2011-07-27 | 2013-01-30 | 东北师范大学 | Method for promoting osteoblast differentiation by using Runx2 and Osterix and application thereof |
US8945894B2 (en) | 2011-09-28 | 2015-02-03 | Courtney M. Creecy | Alternating electric current directs, enhances, and accelerates mesenchymal stem cell differentiation into either osteoblasts or chondrocytes but not adipocytes |
WO2013049598A1 (en) * | 2011-09-28 | 2013-04-04 | Board Of Regents Of The University Of Texas System | Alternating electric current directs, enhances, and accelerates mesenchymal stem cell differentiation into osteoblasts and chondrocytes but not adipocytes |
Also Published As
Publication number | Publication date |
---|---|
KR20060124654A (en) | 2006-12-05 |
CN1898378A (en) | 2007-01-17 |
AU2004299704A1 (en) | 2005-06-30 |
GB0329310D0 (en) | 2004-01-21 |
US8469034B2 (en) | 2013-06-25 |
CA2550084A1 (en) | 2005-06-30 |
EP1699917A2 (en) | 2006-09-13 |
JP2007518710A (en) | 2007-07-12 |
WO2005059118A3 (en) | 2006-05-26 |
US20110034753A1 (en) | 2011-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8469034B2 (en) | Stem cell targeting and activation using magnetic particles | |
Rittchen et al. | Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF) | |
Li et al. | Adaptive materials based on iron oxide nanoparticles for bone regeneration | |
Polak et al. | Nanometric agents in the service of neuroscience: manipulation of neuronal growth and activity using nanoparticles | |
Kopke et al. | Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant | |
Whatley et al. | Magnetic‐directed patterning of cell spheroids | |
Van de Walle et al. | Ever-evolving identity of magnetic nanoparticles within human cells: The interplay of endosomal confinement, degradation, storage, and neocrystallization | |
Ferreira | Nanoparticles as tools to study and control stem cells | |
Funnell et al. | Magnetic composite biomaterials for neural regeneration | |
Lopez et al. | Magneto-mechanical destruction of cancer-associated fibroblasts using ultra-small iron oxide nanoparticles and low frequency rotating magnetic fields | |
WO2006048321A1 (en) | Multimodally modified cells used as an administrable form for active substances and as diagnostic particles | |
Aseri et al. | Magnetic nanoparticles: Magnetic nano-technology using biomedical applications and future prospects | |
Zou et al. | MUC‐1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment | |
Gao et al. | Magnetic field promotes migration of schwann cells with chondroitinase ABC (ChABC)-loaded superparamagnetic nanoparticles across astrocyte boundary in vitro | |
Xia et al. | Manipulation of Schwann cell migration across the astrocyte boundary by polysialyltransferase-loaded superparamagnetic nanoparticles under magnetic field | |
US7625562B2 (en) | Generation of cartilage using magnetizable particles | |
Ahn et al. | Biodistribution of poly clustered superparamagnetic iron oxide nanoparticle labeled mesenchymal stem cells in aminoglycoside induced ototoxic mouse model | |
WO2000071169A2 (en) | Magnetic resonance tracking of magnetically labeled cells | |
Huang et al. | 3D gradient and linearly aligned magnetic microcapsules in nerve guidance conduits with remotely spatiotemporally controlled release to enhance peripheral nerve repair | |
Almeida et al. | Magnetic triggers in biomedical applications–prospects for contact free cell sensing and guidance | |
Bharti et al. | Nanotechnology in stem cell research and therapy | |
Zhang et al. | Polarization of stem cells directed by magnetic field-manipulated supramolecular polymeric nanofibers | |
Yoo et al. | In vivo fluorescence imaging of threadlike tissues (Bonghan ducts) inside lymphatic vessels with nanoparticles | |
Yanada et al. | Effects of CD44 antibody–or RGDS peptide–immobilized magnetic beads on cell proliferation and chondrogenesis of mesenchymal stem cells | |
Rotherham et al. | Remote magnetic actuation of cell signalling for tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480038043.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004299704 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 547910 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067012067 Country of ref document: KR Ref document number: 2550084 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006544539 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2004299704 Country of ref document: AU Date of ref document: 20041208 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004299704 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004805976 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004805976 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067012067 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10596594 Country of ref document: US |